pharmacopeia

Rubidium

US-FDASourced from openFDA
GET
/api/v1/drug/rubidium

Approval history

Sourced from openFDA
  • Dec 29, 1989NDANDA019414Bracco
  • Sep 30, 2016NDANDA202153Jubilant

FAERS reports

View JSON
Reference statistics only. FAERS reports are voluntarily submitted and are not incidence rates, safety signals, or causal evidence. Counts reflect reporting volume — how often a reaction was reported, not how often it occurs. For decision-grade use, consult openFDA and the FAERS Public Dashboard directly.
130 total reports matchedLatest report Share = reports listing the reaction ÷ total matched reports. Rows can sum to >100% because a single report often lists multiple reactions.
  1. 1No Adverse Event7658%
  2. 2Expired Product Administered2620%
  3. 3Product Preparation Error2620%
  4. 4Wrong Technique In Product Usage Process2318%
  5. 5Drug Ineffective118.5%
  6. 6Radiation Overdose86.2%
  7. 7Underdose75.4%
  8. 8Off Label Use64.6%
  9. 9Exposure To Radiation53.8%
  10. 10Therapeutic Response Unexpected43.1%
  11. 11Wrong Technique In Drug Usage Process43.1%
  12. 12Device Use Error32.3%
  13. 13Drug Effect Decreased32.3%
  14. 14Intercepted Product Administration Error32.3%
  15. 15Product Quality Issue32.3%

Literature

View JSON

Recent PubMed references pinned to Rubidium as a MeSH major topic. Citations link to pubmed.ncbi.nlm.nih.gov.

Clinical trials

View JSON

The 10 most recently updated of 22 ClinicalTrials.gov registrations naming Rubidium as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.

Note. Data for rubidium is illustrative MVP content compiled from public sources. pharmacopeia is for educational and informational use only and is not a substitute for professional medical advice.

Search pharmacopeia

Search drugs, classes, and ingredients